Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART by Bertrand, Julie et al.
Influence of pharmacogenetics on indinavir disposition
and short-term response in HIV patients initiating
HAART
Julie Bertrand, Jean-Marc Treluyer, Xavie`re Panhard, Agnes Tran, Solange
Auleley, Elisabeth Rey, Dominique Salmon-Ce´ron, Xavier Duval, France
Mentre´
To cite this version:
Julie Bertrand, Jean-Marc Treluyer, Xavie`re Panhard, Agnes Tran, Solange Auleley, et al..
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients
initiating HAART. European Journal of Clinical Pharmacology, Springer Verlag, 2009, 65 (7),
pp.667-678. <10.1007/s00228-009-0660-5>. <hal-00534961>
HAL Id: hal-00534961
https://hal.archives-ouvertes.fr/hal-00534961
Submitted on 11 Nov 2010
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
SPECIAL ARTICLE
Influence of pharmacogenetics on indinavir disposition
and short-term response in HIV patients initiating HAART
Julie Bertrand & Jean-Marc Treluyer &
Xavière Panhard & Agnes Tran & Solange Auleley &
Elisabeth Rey & Dominique Salmon-Céron &
Xavier Duval & France Mentré &
the COPHAR2-ANRS 111 Study Group
Received: 12 January 2009 /Accepted: 7 April 2009 /Published online: 14 May 2009
# Springer-Verlag 2009
Abstract
Aims To assess the relationship between genetic poly-
morphisms and indinavir pharmacokinetic variability and
to study the link between concentrations and short-term
response or metabolic safety.
Methods Forty protease inhibitor-naive patients initiating
highly active antiretroviral therapy (HAART) including
indinavir/ritonavir and enrolled in the COPHAR 2–ANRS
111 trial were studied. At week 2, four blood samples were
taken before and up to 6 h following drug intake. A population
pharmacokinetic analysis was performed using the stochastic
approximation expectation maximization (SAEM) algorithm
implemented in MONOLIX software. The area under the
concentration–time curve (AUC) and maximum (Cmax) and
trough concentrations (Ctrough) of indinavir were derived
from the population model and tested for their correlation
with short-term viral response and safety measurements,
while for ritonavir, these same three parameters were tested
for their correlation with short-term biochemical safety
Results A one-compartment model with first-order absorp-
tion and elimination best described both indinavir and
ritonavir concentrations. For indinavir, the estimated clear-
ance and volume of distribution were 22.2 L/h and 97.3 L,
respectively. The eight patients with the *1B/*1B genotype
for the CYP3A4 gene showed a 70% decrease in absorption
compared to those with the *1A/*1B or *1A/*1A genotypes
(0.5 vs. 2.1, P=0.04, likelihood ratio test by permutation).
The indinavir AUC and Ctrough were positively correlated
with the decrease in human immunodeficiency virus RNA
between week 0 and week 2 (r= 0.4, P=0.03 and r =-0.4,
P=0.03, respectively). Patients with the *1B/*1B genotype
also had a significantly lower indinavir Cmax (median 3.6,
range 2.1–5.2 ng/mL) than those with the *1A/*1B or *1A/
*1A genotypes (median 4.4, range 2.2–8.3 ng/mL) (P=0.04)
Eur J Clin Pharmacol (2009) 65:667–678
DOI 10.1007/s00228-009-0660-5
J. Bertrand (*)
UMR 738,
INSERM, Université Paris Diderot,
UFR de Médecine, 16, rue Henri Huchard,
75018 Paris, France
e-mail: julie.bertrand@inserm.fr
J.-M. Treluyer
EA3620,
Université Paris Descartes,
Paris, France
J.-M. Treluyer
Service de Pharmacologie Clinique,
Hôpital Cochin-Saint-Vincent-de-Paul, AP-HP,
Paris, France
X. Panhard : F. Mentré
UMR 738, AP-HP,
INSERM, Université Paris Diderot,
Paris, France
A. Tran : E. Rey
Service de Pharmacologie Clinique,
Hôpital Cochin-Saint-Vincent-de-Paul, AP-HP,
Paris, France
S. Auleley :X. Duval
UMR 738, INSERM, Université Paris Diderot,
Paris, France
D. Salmon-Céron
Service de Médecine Interne,
Hôpital Cochin-Saint-Vincent-de-Paul, AP-HP,
Paris, France
X. Panhard : F. Mentré
UF de Biostatistiques, Hôpital Bichat,
Paris, France
X. Duval
Centre d’Investigation Clinique, Hôpital Bichat, AP-HP,
Paris, France
and a lower increase in triglycerides during the first 4 weeks
of treatment (median 0.1, range −0.7 to 1.4 vs. median 0.6,
range −0.5 to 1.7 mmol/L, respectively; P=0.02). For
ritonavir, the estimated clearance and volume of distribution
were 8.3 L/h and 60.7 L, respectively, and concentrations
were not found to be correlated to biochemical safety.
Indinavir and ritonavir absorption rate constants were found
to be correlated, as well as their apparent volumes of
distribution and clearances, indicating correlated bioavail-
ability of the two drugs.
Conclusion The CYP3A4*1B polymorphism was found to
influence the pharmacokinetics of indinavir and, to some
extent, the biochemical safety of indinavir.
Keywords CYP3A4 . Efficacy .
Nonlinear mixed effects modeling . Pharmacokinetics .
Protease inhibitors . Safety
Introduction
Indinavir has been one of the preferred protease inhibitor
(PI) included in highly active antiretroviral therapy (HAART).
Even if not recommended as initial therapy, indinavir is
currently still used in patients who initiated their therapy
with this PI and have kept a viral load below the limit of
quantification with an acceptable safety profile. Compared to
others PI, indinavir exhibits a high penetration into viral
reservoirs, such as genital compartments and the central
nervous system (CNS) [1], and it has been determined that
the better distribution of indinavir leads to better outcomes in
neurological complications related to human immunodefi-
ciency virus (HIV) [2]. The pharmacokinetics (PK) of
indinavir is characterised by high maximal concentrations,
leading to potential toxicity, notably nephrolithiasis [3], and
low minimum concentrations with respect to the 95%
inhibitory concentration of the virus. These low residual
concentrations result from an extended oxidative metabolism
by the cytochrome P450 (CYP) 3A isoenzyme [4]. The co-
administration of ritonavir, whose molecular structure leads
to CYP3A inhibition, therefore enhances exposure to
indinavir [5, 6]. Ritonavir is given at a lower dose as a
booster than for therapeutic use, but it has been shown
nevertheless to influence metabolic profiles, especially those
associated with lipid disorders [7, 8].
The large inter-patient and intra-patient variability of
indinavir pharmacokinetics is well referenced [9–11].
Genetic polymorphisms partly explain this variability, as
far as the proteins involved in the metabolism and transport
of PI are concerned. However, few studies have investigat-
ed the impact of ABCB1 polymorphisms, a gene coding for
P-glycoprotein, and CYP3A5 and CYP3A4*1B polymor-
phisms on indinavir pharmacokinetics. Solas et al. [12]
reported that the ABCB1 C3435T genotype affects the
absorption constant of indinavir, whereas Verstuyft et al.
[13] found an absence of association. Anderson et al. [14]
observed that CYP3A5 expressors (CYP3A5*1 carriers) have
a significantly faster oral clearance than non-expressors. To
date, no relationship has been found between the
CYP3A4*1B polymorphism and alterations in CYP3A
substrate metabolism, but clinical data have shown an
association between the CYP3A*1B polymorphism and
disease risk/treatment toxicity [15].
Efficacy [16, 17] as well as adverse events [3, 18] have
been related to indinavir plasma concentrations. Thus,
therapeutic drug-monitoring appears to be a potent tool to
achieve undetectable HIV-RNA and prevent toxicity for
this drug. The COPHAR 2–ANRS 111 trial is a multi-
centre, non-comparative pilot trial of early therapeutic drug-
monitoring in HIV-positive patients naive for PI-containing
HAART [19]. We focused on the PK sub-study from the
group of patients receiving indinavir boosted with ritonavir.
The aims of this paper were to estimate the population PK
parameters and variability of indinavir and ritonavir in HIV
patients, to evaluate the impact of genetic polymorphisms
on indinavir PK and to study the link between indinavir
concentrations and short-term efficacy and metabolic safety.
Methods
Study
The COPHAR 2–ANRS 111 study is a multi-centre non-
comparative prospective pilot trial of early-dose adaptation
in HIV-positive PI-naive patients starting a PI-containing
HAART treatment. The trial started on July 2002 and was
completed by the end of March 2005. The objective was to
assess the benefit of pharmacological advice based on
trough plasma concentrations of PI. The study involved
three groups treated with indinavir, nelfinavir or lopinavir,
respectively. In the study reported here we analysed the
data obtained during the first month of treatment in the
indinavir group. A similar analysis of data in the nelfinavir
group was performed by Hirt et al. [19, 20; see these papers
for details].
Patients were required to have a baseline plasma viral
load value >1000 copies/mL and to be PI treatment-naive.
Patients were started on a HAART treatment containing
400, 600 or 800 mg of indinavir twice daily (b.i.d.)
associated with ritonavir booster (100 mg b.i.d.) and two
nucleoside analogues. The first dose was left to the treating
physicians’ discretion, and no dose adaptation was per-
formed from week 0 (W0) to W4. A detailed PK study was
performed at W2. Adherence was evaluated at W2 by
means of a validated auto-questionnaire [21], and patients
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were classified as adherent when they reported no shift in
their treatment schedule during the last 4 days; in all other
cases, they were classified as non-adherent.
Data on viral load and CD4 count were collected at
baseline (D0) and at W2. Biochemical profiles of total
cholesterol, high-density lipoprotein cholesterol, triglyceride
and glycaemia as well as creatinine clearance and clinical
events (diarrhoea grade of 2) were determined 4 weeks
before treatment initiation (W−4) and at W4.
The study was performed in accordance with the
Declaration of Helsinki and its amendments. All subjects
provided written informed consent, and the protocol as
well as the amendment for the pharmacogenetic study was
approved by the Ethics Committee of the Bicêtre Hospital
(France).
Indinavir and ritonavir concentration measurements
During a visit to the hospital at W2, the patients were
sampled on arrival to measure trough concentrations.
Patients were asked to record the time at which the dose
was taken on the previous evening, given their medications,
and then sampled again 1, 3 and 6 h after drug administra-
tion. Plasma concentrations were assumed to be at steady
state with trough concentrations considered as following the
drug intake using the delay reported by the patient the from
previous dosing. Plasma concentrations were determined
in the laboratories of the hospitals by a specific high-
performance liquid chromatography protocol. The partic-
ipant laboratories were cross-validated before starting the
study. Results of the blind inter-laboratory quality control
at three concentrations for indinavir and for ritonavir were
within 15% of the target values for medium and high
values and within 20% for low values. Lower limits of
quantification (LOQ) were 0.02 mg/L for indinavir and
0.025 mg/L for ritonavir.
Genetic polymorphisms
All of the genotyping analyses were performed in the
same laboratory. Total DNA was extracted from plasma
samples using the QIAamp DNA Blood Mini kit (Qiagen,
Courtaboeuf, France). ABCB1 polymorphisms in exons
21 (GG, GT, TT) and 26 (CC, CT, TT) were determined
using previously published methods [22]. The genotyping
of CYP3A5 (*1*1, *1*3, *3*3, *1*6, *6*6) was performed
by real-time PCR applying TaqMan MGB probe technology
(Applied Biosystems, Foster City, CA). Genotyping for
CYP3A4 (*1B*1B, *1B*1A, *1A*1A) was determined by
PCR, followed by direct sequencing. The PCR analysis was
performed using a GenAmp PCR System 9700 (Applied
Biosystems) according to a previously published method
[23]. Amplified DNAwas purified using the QiaQuick DNA
Purification System (Qiagen) and sequenced using BigDye
Terminator chemistry and an ABI PRISM 3100 genetic
analyser (Applied Biosystems). At least two positive controls
were used for each genotyping analysis: one homozygous for
the wild-type allele and one heterozygous (and, when
available, one homozygous) for the mutated allele. These
controls were DNA that had already been sequenced.
Allele frequencies (p for the wild allele and q=1 − p for
the mutant allele) were estimated by gene counting.
Departure from Hardy–Weinberg proportions (p2, 2pq, q2)
was tested by a χ2 test with 1 df within each ethnic group
[24]. We used two approaches to define patients belonging
to an ethnic group: (1) classification of the patient according
to town, birth area and nationality; (2) classification by
means of genotype information using the Structure software
[25]. This software is based on a Bayesian approach and
computes the a posteriori probabilities of each individual of
belonging to a given ethnic group. We assumed each locus to
be at the Hardy–Weinberg equilibrium and patients to
originate in one ethnic group (with its own characteristic
set of allele frequencies).
Population PK analysis
We used a population approach to analyse the concentra-
tion–time data at W2 for indinavir and for ritonavir
separately. Model fitting and estimation of the population
model parameters were performed using the stochastic
approximation expectation maximization algorithm (SAEM)
for nonlinear mixed-effects models implemented in the
MONOLIX software ver. 2.1 [26–28]. Both indinavir and
ritonavir concentrations were fitted by a one-compartment
model with first-order absorption and first-order elimination
parameterised in the absorption rate constant (ka), oral
clearance (Cl/F) and oral volume of distribution (V/F).
Each model was assumed at steady state with trough
concentrations considered as following the drug intake.
An exponential model was used for inter-individual
variability where random effects were assumed to follow a
normal distribution with zero mean and diagonal variance
matrix. Additive, proportional and combined error models
were tested, and model choice was based on the likelihood
ratio test (LRT) and goodness-of-fit plots (observed vs.
predicted population and individual concentrations; popu-
lation and individual weighted residuals vs. predicted
concentrations and vs. time). We performed a visual
predictive check (VPC) with 1000 simulated data sets to
evaluate the basic model [29].
Interaction between ritonavir and indinavir PK was
evaluated with the individual parameters estimated from
the basic model for each drug. All of the different
correlations were tested with the Spearman non-parametric
correlation test.
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Assessment of the effect of covariates
The effects of the following covariates were evaluated from
the basic model: dose, concomitant use of the zidovudine
lamivudine combination (AZT/3TC), co-infection by hep-
atitis C or B (VHC/VHB), adherence as previously defined,
sex, ethnic group, the four studied genetic polymorphisms
(ABCB1 exon 26, ABCB1 exon 21, CYP3A5 and CYP3A4)
and the CDC classification for HIV infection as categorical
variables; age, body mass index (BMI), body weight,
creatinine clearance, albumin and orosomucoid levels as
continuous variables. The latter were centered to the median
and log-transformed for model interpretation convenience.
Each of the four genetic polymorphisms was analysed by
means of two binary categorisations: first, wild homozy-
gotes versus heterozygotes or mutant homozygotes; second,
heterozygotes or wild homozygotes versus mutant homo-
zygotes. Categorisation in three classes was also tested:
wild homozygotes versus heterozygotes versus mutant
homozygotes. Missing continuous covariates were replaced
with the median, and patients with missing discrete cova-
riates were discarded for the corresponding analysis. The
effects of covariates on the empirical Bayes estimates (EBE)
of each individual PK parameter from the basic model were
tested with the Wilcoxon non-parametric test for categorical
variables and the Spearman non-parametric correlation test
for continuous variables. The population covariate model
was built with the covariates, which were found to have an
effect in this first step with a P value<0.1. When a genetic
covariate was found to have an effect whatever the
categorisation, the same categorisation as other genetic
covariates also found to have an effect was chosen in model
selection for consistency.
A forward selection of these covariates for the population
model was performed using the LRT with a significance
threshold at P<0.05. From this ascending method, a
backward elimination procedure was performed. In order
to correct the inflation of the LRT type I error on small
sample size [30], the backward selection was realized using
permutation [31]. More specifically, 1000 data sets are
generated by permuting the rows of the covariates matrix
from the original data set. For each covariate, one likelihood
ratio statistic, LRTobs, is estimated from the original data
and one likelihood ratio statistic, LRTperm, is estimated
from each of the 1000 data sets. Thus, we obtain
j ¼ 1; :::; 1000 LRTpermj . The permutation P value is the
proportion : card LRTpermj > LRTobs
 
1000.
Short-term efficacy and safety and link with concentrations
As there was no change of dose before W4, we studied the
link between concentration at W2 and efficacy or safety
during the first 2 or 4 weeks of treatment. For short-term
efficacy, the difference of log viral load between the day of
treatment initiation and W2 (Δ logVL) was studied. The
significance of the viral load decrease was tested by a
Wilcoxon non-parametric paired test.
Individual area under the concentration–time curve
(AUC), maximal plasma concentration (Cmax) and trough
concentrations (Ctrough) of indinavir at steady-state were
derived for each patient using the EBE of the individual
parameters from the basic model and their corresponding
dose of indinavir. The relationship between indinavir dose,
indinavir AUC, Cmax, Ctrough and Δ logVL was evaluated
using the Spearman correlation test. A Wilcoxon non-
parametric test was performed to compare the Δ logVL
between patients with or without a Ctrough below the lower
limit of the therapeutic range used in the COPHAR 2–
ANRS 111 trial: 150 ng/mL.
Safety was analysed by determining the difference between
4 weeks before and 4 weeks after treatment initiation in terms
of total cholesterol (ΔTC), high-density lipoprotein choles-
terol (ΔHDL), triglyceride (Δtrig) and glycaemia (Δgly) and
also by the appearance of diarrhoea (grade 2) between
treatment initiation and W4. To the best of our knowledge,
no precocious biological markers exist for nephrolithiasis;
however, creatinine clearance has been found to relate to the
occurrence of severe adverse events (including nephrolithia-
sis) in a multivariate analysis [3]. Thus, we also analysed the
difference in creatinine clearance (ΔClCr), computed with
the Cockcroft–Gault formula using body weight and serum
creatinine 4 weeks before and 4 weeks after treatment
initiation. The significance of these differences was tested
using a Wilcoxon non-parametric paired test.
We performed Spearman correlation tests between
indinavir dose, indinavir AUC, Cmax , Ctrough and ΔTC,
ΔHDL, Δtrig, Δgly and ΔClCr. We used Wilcoxon non-
parametric tests to compare these differences between
patients with or without an indinavir Ctrough over the upper
limit defined in the therapeutic index (550 ng/mL). We
studied the link between the appearance of grade 2
diarrhoea (yes/no) between treatment initiation and W4
and indinavir dose, indinavir AUC, Cmax and Ctrough using a
Wilcoxon non-parametric test, and we studied the associ-
ation with or without an indinavir Ctrough > 550 ng/mL
using a Fisher exact test.
We assessed the relation between the genetic poly-
morphisms remaining in the final population model and
indinavir dose, indinavir AUC, Cmax and Ctrough and the
relation between these genetic polymorphisms and the
short-term efficacy and safety outcomes using Wilcoxon
non-parametric tests.
We also derived AUC, Cmax and Ctrough for ritonavir and
performed Spearman correlation tests with ΔTC, ΔHDL, Δ
trig, Δgly and ΔClCr as well as Wilcoxon non-parametric
tests on the appearance of grade 2 diarrhoea.
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Results
Patients
Forty-two patients were included in this treatment group of
the COPHAR 2 ANRS–111 trial. However, one patient
withdrew from the study, and one switched to another PI
during the first week of treatment. We therefore obtained
PK data from 40 patients (27 men, 13 women) with a
median age of 36.5 years (range 20.0–59.0 years). Table 1
summarizes the main characteristics of the patient cohort.
Both of the approaches used to allocate the ethnic group
provided corroborating results. Using the civic information
we allocated 20 patients to the African group and 20 to the
Caucasian group. Because information for all genotypes
was missing for all genotypes, the Structure software
allocated 19 patients to the Caucasian group and 20 to the
African group. In the resulting two ethnic groups, Hardy–
Weinberg proportions were respected for all polymorphisms
under study, as shown in Table 2.
Indinavir pharmacokinetics
Two samples were missing, the trough and the 6 h
concentrations, for two patients, and only the trough concen-
tration was available for a second patient. Among the 155
samples, two indinavir plasma concentrations in one patient
were below the LOQ (at 1 h and at trough), and these were
discarded from further analysis. Figure 1a shows the plot of
indinavir plasma concentrations at W2 versus time, revealing
a high inter-individual variability.
The best error model was a proportional error model.
The population estimates are displayed in Table 3. All of
the relative standard errors (RSE) were below 25% with the
exception of ka and ωV/F (around 30 and 60%, respectively).
The inter-individual variance of ka in this study was rather
important (above 100%). The simulated median and the 90th
interval are given in Fig. 2a together with all of the observed
concentrations of indinavir. This graph provides good
evidence of the adequacy of the model.
From that basic model, we first tested the effects of the
covariates on the individual parameter estimates. Effects of
age (P=0.03) and the ABCB1 exon 26 polymorphism (P=
0.09) on Cl/F and of the Centers for Disease Control (CDC)
classification (P=0.09) and the CYP3A4*1B polymorphism
(P=0.09) on ka were found. Both ABCB1 exon 26 and the
CYP3A4*1B polymorphism variables were dichotomised in
mutant homozygotes versus other genotypes. Following a
forward selection based on LRT, the population model
had CYP3A4 effect on ka (P=0.02) and an age effect on
Cl/F (P =0.03). The age effect on clearance was withdrawn
from the model after the backward selection based on the
permutation test. In the final model, the absorption rate
constant was decreased by 70% (P=0.04, LRT by permuta-
tion) in patients with the *1B*1B genotype for the CYP3A4
allele:
ka ¼ 2:1 e1:3CYP3A4with CYP3A4 ¼ 0 for patients CYP3A4  1A  1A or CYP3A4  1A  1BCYP3A4 ¼ 1 for patients CYP3A4  1B  1B :

Characteristics of the patients Median (range)
Age (years) 36.5 (20.0–59.0)
BMI (kg/m2 ) 22.6 (17.5–35.8)
Weight (kg) 68.0 (45.0–103.0)
Creatinine clearance (mmol/L) 95.4 (57.4–245.1)
Albumin (g/L) 38.4 (25.5–47.4)
Orosomucoid (g/L) 1.0 (0.5–2.9)
Number of patients (%)
Dose (400/600/800 mg) 26 (65)/8 (20)/6 (15)
Coadministration of AZT/3TC (y/n) 33 (83)/ 7 (17)
Coinfection VHB/VHC (yes/no)a 7 (18)/32 (82)
Good adherence (yes/no) 15 (38)/25 (62)
Sex (male/female) 27 (68)/13 (32)
Ethnic group (African/Caucasian) 20 (50)/20 (50)
CDC classification for HIV infection (A or B/C) 30 (75)/10 (25)
Table 1 Characteristics of the
patient cohort (n = 40)
BMI, Body mass index; AZT/
3TC, zidovudine lamivudine
combination; VHC/VHB, co-
infection by hepatitis C or B;
CDC Centers for Disease
Control; HIV, human immuno-
deficiency virus
a Data on one patient are missing
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The population parameters of this final model and their
RSE are given in Table 3 for the 38 patients with data
available genotyping for CYP3A4*1B polymorphism. The
inter-individual variability for ka decreased by 27% from
the basic model with the incorporation of the covariate, and
residual variability was 44.7%.
Ritonavir pharmacokinetics
For one patient, only data on the indinavir concentrations
were available and there was no data on ritonavir concentra-
tion; consequently, we only analysed ritonavir data for 39
patients. The same five samples for indinavir mentioned in
the preceding section were also missing. Among the 151
samples, two ritonavir plasma concentrations at 1 h and at
trough in one patient and one concentration at 12 h in another
patient were below the LOQ and were discarded. Observed
plasma concentrations are given in Fig. 1b, and it should be
noted that some patients showed high plasma concentra-
tions (above 2000 ng/mL) for a dose of 100 mg b.i.d.
A proportional error model was selected. The population
estimates are displayed in Table 4. All of the RSE were below
25% with the exception of ka; this was partly attributable to
the sparse design and to the ωCl/F, as observed for the
indinavir data. The VPC obtained with the basic model
parameters estimates is given in Fig. 2b, together with the
concentrations observed.
The results of the basic model evaluation were very
satisfactory.
Effects of orosomucoid (P=0.03), albumin levels (P=
0.04) and CYP3A5 polymorphism (patients with two wild
alleles at most vs. other genotypes, P=0.04) on Cl/F were
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Table 2 Distribution of the genetic polymorphisms within each ethnic group and Hardy–Weinberg P values
Genetic polymorphisms Number of patients (%) H-W P-value
African
ABCB1 exon 26 (CC/CT/TT) 11 (55)/9 (45)/ 0 (0) 0.43
ABCB1 exon 21 (GG/GT/TT) 19 (95)/1 (5)/ 0 (0) 0.99
CYP3A5 (4*1/3*1/_2*1) 0 (0)/8 (40)/12 (60) 0.53
CYP3A4*1B (*1A*1A/*1A*1B/*1B*1B) 9 (45)/8 (40)/3 (15) 0.86
Caucasian
ABCB1 exon 26 (CC/CT/TT) 2 (12)/12 (70)/3 (18) 0.22
ABCB1 exon 21 (GG/GT/TT) 4 (21)/11 (58)/4 (21) 0.79
CYP3A5 (4*1/3*1/_2*1) 18 (100)/0 (0)/0 (0) 1
CYP3A4*1B (*1A*1A/*1A*1B/*1B*1B) 0 (0)/3 (16)/16 (84) 0.93
H-W P value, Hardy–Weinberg P value according to the H–W proportions test
Data on all genotypes were missing for one patient; data on the ABCB1 exon 26 and CYP3A4 genotypes were both missing for a second patient;
data on the genotype for ABCB1 exon 26 were missing for a third patient
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found on the individual parameters by the non-parametric
tests, as were effects of HIV disease status (P=0.05) on
kaand creatinine clearance (P=0.1) on V/F. In the final
model, an increase of 0.5 g/L in orosomucoid from the
median (1 g/L) was associated with a clearance decrease of
28% (P=0.03, LRT by permutation):
Cl

F ¼ 8:3 Orosomucoid0:8
The population parameters of this model and their RSE
are given in Table 4.
Link between indinavir and ritonavir PK parameters
Four positive correlations between individual parameters of
ritonavir and indinavir were found to be significant. There was
a relationship between the indinavir and ritonavir absorption
rate constant (r=0.4, P=0.005). Indinavir clearance was
strongly correlated to ritonavir clearance (r=0.6, P <0.0001)
and to a smaller degree to ritonavir volume of distribution
(r=0.4, P <0.01), while indinavir volume of distribution was
highly correlated to ritonavir volume of distribution (r=0.5,
P < 0.002).
Concentrations link with short-term efficacy and safety
There was a significant decrease in viral load in the first 2
weeks of treatment, and a significant increase in total
cholesterol, glycaemia and triglycerides in the first 4 weeks
of treatment, as shown in Table 5.
The decrease in log viral load was significantly associated
with higher indinavir AUC (r= −0.4, P=0.03) and Ctrough (r=
−0.4, P=0.03), as shown in Fig. 3. No significant difference
in viral load decrease was found between the five patients
with a Ctrough below the lower limit of the therapeutic range
and the 35 patients with a Ctrough above this value.
Further, no significant relationship was found between
indinavir nor ritonavir concentrations and safety measure-
ments or grade 2 diarrhoea. No nephrolithiasis has been
reported in the COPHAR 2–ANRS 111 trial, which has
prevented us from analysing the link between concentra-
tions and this adverse event associated with indinavir.
The genetic covariate kept in the final population PK
model was the CYP3A4*1B polymorphism categorised in
two classes: *1B*1B versus other genotypes. Both Cmax
and increase in triglycerides were found to be significantly
associated with the CYP3A4*1B polymorphism, although
the correlation was not significant. the Cmax was signifi-
cantly lower in patients homozygous for the *1B allele
(median 3.6, range 2.2–5.2 ng/mL) than in the other groups
(mean 4.4, range 2.2–8.3 ng/mL) (P=0.04), and the
increase in triglycerides was also significantly smaller
(mean 0.1, range −0.7 to 1.4 vs. mean 0.6, range −0.5 to
1.7 mmol/L, respectively; P=0.02), as illustrated by Fig. 4.
In terms of the efficacy, no significant association was
found between the CYP3A4*1B*1B genotype and the
Ctrough or the log viral decrease.
The various doses of indinavir were not found to be
associated with the CYP3A4*1B polymorphism, short-term
Parameters Basic model (n=39) Covariate model (n=39)
Estimates RSE (%) Estimates RSE (%) Estimates RSE (%) Estimates RSE (%)
ka(h
-1) 2.4 98.7 2.2 93.5
Cl/F (L/h) 8.7 9.4 8.3 9.0
bOrosomucoidCl Z - - –0.8 46.5
V/F (L) 61.6 8.6 60.7 8.7
ωka (%) 357.7 21.9 346.8 21.5
ωCl/F (%) 55.9 12.2 52.4 12.4
ωV/F (%) 22.8 53.9 23.3 51.5
σ (%) 30.4 8.4 30.3 8.4
Table 4 Population pharmaco-
kinetic parameters of ritonavir
for the basic and the final
model: estimates and RSE
Table 3 Population pharmacokinetic parameters of indinavir for the
basic and the final model: estimates and relative standard error
Parameters Basic model (n=40) Covariate model (n=38)
Estimates RSE (%) Estimates RSE (%)
ka(h
−1) 1.3 33.7 2.1 44.1
bCYP3A4ka - - -1.3 42.0
Cl/F (L/h) 21.9 6.9 22.2 6.9
V/F (L) 93.9 8.2 97.3 9.3
ωka (%) 118.0 22.9 98.2 28.7
ωCl/F (%) 34.4 15.0 34.9 15.0
ωV/F (%) 19.3 66.8 21.6 57.8
σ(%) 44.5 8.9 44.7 8.6
ka, absorption rate constant; Cl/F, oral clearance; V/F, oral volume of
distribution; RSE, relative standard error
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efficacy or safety, which negated its potential confounding
effect.
Discussion
The PK of indinavir was analysed using a one-compartment
model with first-order absorption and elimination at steady-
state. The estimated clearance and volume of distribution
were 22.2 L/h and 97.3 L, respectively, both of which are in
the range of those obtained in previous studies [9, 11, 32].
In this study, ABCB1 exons 26 and 21 and the CYP3A5*3
and *6 polymorphisms were not found to significantly
influence the PK of indinavir: the absorption rate was 0.6 h−1
for CYP3A4*1B*1B patients and 2.1h−1for CYP3A4*1A*1A
or CYP3A4*1A*1B patients. The CYP3A enzymes are
distributed in both hepatocytes and enterocytes [33] and
their inhibition by ritonavir is well-documented [34–36]. In
vivo, the genotype–phenotype correlation for CYP3A4*1B
remains a subject of debate [37–40]; however, CYP3A4*1B
has been related to increased transcription [41] in vitro. We
hypothesised that in CYP3A4*1B*1B patients, the ritonavir
inhibition potency is lowered, leading to a higher first pass
effect of indinavir, although this does not impact on its
clearance. The potential confounding effect of the ethnic
group was discarded, as this covariate was not significantly
related to indinavir individual parameters in the sample.
However, this finding is more relevant clinically in an
African population given the extremely low frequency of the
CYP3A4*1B*1B genotype among Caucasians. The primary
objective of the COPHAR2 study was not to assess the
influence of genetic polymorphisms on indinavir PK, and the
use of modelling has helped to circumvent the limited
sample size of 40 patients in the study. In addition, most of
Table 5 Median and range of the studied short-term efficacy and safety measurements and of the change from baseline
Short-term efficacy and safety measurements Baselinea W2 or W4b Difference from baseline P value
Efficacy
Log viral load (log copies/mL) 4.9 (3.4–6.3) 2.9 (1.8–4.1) −1.8 (–2.8 to −0.5] <0.001
Safety
Total cholesterol (mmol/L) 4.3 (1.9–7.4) 5.0 (2.9–7.5) 0.8 (0.8–4.7) <0.001
HDL cholesterol (mmol/L) 1.1 (0.5–1.8) 1.1 (0.4–2.1) 0.1 (– 0.7–1.0) 0.09
Glycaemia (mmol/L) 4.7 (3.4–6.0) 4.9 (2.8–7.1) 0.2 (−1.0 to 2.7) 0.013
Triglycerides (mmol/L) 1.0 (0.4–3.0) 1.4 (0.6–4.0) 0.4 (−0.7 to 1.7) <0.001
Creatinine clearance (mL/min) 98.4 (62.0–195.7) 97.4 (62.8–252.0) −1.0 (−38.0 to 56.4) 0.5
HDL, High-density lipoprotein
a Baseline = Day 0 for log viral load and week (W) 4 for safety
bWeek 2 for log viral load and week 4 for safety
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the tests in this study were performed as an exploratory step,
and final inclusion in the model was based on permutation to
cope with departure from the asymptotic assumption [30].
No evidence for a gender effect was found, as has been
reported in a number of other studies on indinavir PK [9–11],
but there were only 13 women in the present study. Dose
has been found not to influence the PK of indinavir, and the
use of ritonavir as a booster has been found to hide the dose
non-linearity of indinavir [42]. We did not assess the impact
of diet, as these data were not available, but patients were
recommended to ingest the pills with food containing a
sufficient amount of fats.
We also performed a population PK analysis of ritonavir
concentrations. Ritonavir profiles were adequately described
by a one-compartment model with first-order absorption and
elimination processes, with estimates of the parameters being
in good agreement with those of previous studies [6, 43, 44].
The estimated inter-individual variance for the absorption
constant was singularly large. We found a negative relation-
ship between ritonavir clearance and orosomucoid level in
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plasma. The affinity of ritonavir for orosomucoid protein as
well as its impact on PI intracellular concentrations and
efficacy has been described in both in vitro and in vivo
studies [45–47]. In patients with high orosomucoid plasma
levels, the decrease in the unbound fraction of ritonavir led
to a lower clearance.
In the analysis of both PI, the few concentrations (1.3
and 2% for indinavir and ritonavir, respectively) below the
LOQ were discarded. Using this approach, SAEM acquires
a less important bias than it would with LOQ/2 [48]. There
is no proper method in MONOLIX 2.1 to handle LOQ.
In the analysis of the link between indinavir and
ritonavir concentrations, we chose not to include ritonavir
as a covariate in the indinavir model, as performed in
previous studies [10, 11]. Indeed, such parameterisation
assumes a unidirectional influence of ritonavir on indinavir,
which is not true. Ritonavir concentrations, when ritonavir
is given with lopinavir, are lower than when ritonavir is
given with indinavir [44]. We have instead emphasised
the different levels of interaction between indinavir and
ritonavir PK, especially at the absorption step, with the
strong correlation between their absorption constant, but
also in terms of bioavailability, as the oral clearances and
volumes of distribution were highly correlated.
In order to properly model such an interaction between
PI, a joint population analysis of concentrations of indinavir
and ritonavir should be considered with correlated absorp-
tion constants and bioavailabilities.
We observed significant changes in viral load after 2 weeks
of treatment, and we confirmed the association between high
indinavir trough and mean concentrations and a greater
decrease of viral load, which has already been described in
PI-naive patients [49–51]. We did not find any relationship
between CYP3A4*1B polymorphism and viral load decrease.
We also observed a significant increase, after 4 weeks of
treatment, of total cholesterol, glycaemia and triglycerides, as
already reported [52], which was, however, not significantly
related to indinavir concentrations at week 2. Ritonavir was
found at singularly high levels in our study and is known to
affect metabolic profiles, yet we found no evidence of an
association between ritonavir levels and safety measure-
ments. In patients homozygous for the CYP3A4*1B allele,
the ritonavir-decreased inhibition on indinavir metabolism
led to significantly lower indinavir Cmax and appeared to
impact at a metabolic level through a significantly lower
increase in triglycerides in these patients.
Conclusion
We have developed and validated models for indinavir and
ritonavir PK with reduced sampling in indinavir HAART
patients. Both the average and trough concentrations were
found to be predictors of the viral load decline. Only the
CYP3A4*1B allele was found to influence indinavir
absorption and biochemical safety, but no evidence was
found of an impact of the five genetic polymorphisms
studied on indinavir efficacy.
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